Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diamyd Medical ABDYMDF 41 Equity-to-Asset is 0.64 as of May. 2026, which is 24% below its 10-year median of 0.84. GuruFocus rates DYMDF with a GF Score™ of 41/100 and a GF Value™ of $9.89. The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Diamyd Medical AB ranks worse than 54.08% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Diamyd Medical AB's Total Stockholders Equity for the quarter that ended in May. 2026 was $27.89 Mil. Diamyd Medical AB's Total Assets for the quarter that ended in May. 2026 was $43.72 Mil.
Therefore, Diamyd Medical AB's Equity to Asset Ratio for the quarter that ended in May. 2026 was 0.64.
The historical rank and industry rank for Diamyd Medical AB's Equity-to-Asset or its related term are showing as below:
DYMDF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.4 Med: 0.84 Max: 0.95
Current: 0.64
During the past 13 years, the highest Equity to Asset Ratio of Diamyd Medical AB was 0.95. The lowest was 0.40. And the median was 0.84.
DYMDF's Equity-to-Asset is ranked worse than 54.08% of 1411
companies
in the Biotechnology industry
Industry Median: 0.68
vs DYMDF: 0.64
Diamyd Medical AB (OTCPK:DYMDF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Diamyd Medical AB Equity-to-Asset Related Terms
Diamyd Medical AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Diamyd Medical AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DYMDF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Diamyd Medical AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Diamyd Medical AB's Equity to Asset Ratio for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamyd Medical AB (DYMDF) has a Equity-to-Asset of 0.64 as of May. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Diamyd Medical AB and its competitors. This is 24% below median its historical median of 0.84. Over the past decade, Diamyd Medical AB's Equity-to-Asset has ranged from 0.40 to 0.95. According to the industry distribution chart, Diamyd Medical AB ranks #763 out of 1411 companies in the Biotechnology industry, placing it in the top 54.1%.
Is Diamyd Medical AB's Equity-to-Asset too high?
Diamyd Medical AB's current Equity-to-Asset of 0.64 is 24% below median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 0.95. The Biotechnology industry median Equity-to-Asset is 0.68. Diamyd Medical AB's value of 0.64 is 5.9% below this industry median. Based on the distribution chart, Diamyd Medical AB ranks #763 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Diamyd Medical AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #763 out of 1411 companies for Equity-to-Asset. This places Diamyd Medical AB in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Diamyd Medical AB's value of 0.64 is 5.9% below this benchmark. Historically, Diamyd Medical AB's own Equity-to-Asset has ranged from 0.40 to 0.95 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 0.68, Diamyd Medical AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diamyd Medical AB's current Equity-to-Asset of 0.64 is 5.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Diamyd Medical AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamyd Medical AB's current Equity-to-Asset is 0.64, which is 24% below median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Diamyd Medical AB (DYMDF) has a current Equity-to-Asset of 0.64. The stock's GF Value™ is $9.89, compared to a current price of $0.73 — trading 92.6% below its estimated fair value. The current Equity-to-Asset is 0.64, which is 24% below median its 10-year median of 0.84 and 5.9% below the Biotechnology industry median of 0.68. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Diamyd Medical AB (DYMDF), the current Equity-to-Asset is 0.64 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (DYMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued.
The current stock price of $0.73 is trading 92.6% below its estimated GF Value™ of $9.89.
Key valuation signals for DYMDF:
Equity-to-Asset: 0.64 (24% below median its 10-year median of 0.84)
GF Value™: $9.89 vs. price of $0.73 (92.6% below fair value)
Industry Position: 5.9% below the Biotechnology median (#763 of 1411)
No single metric tells the full story. See the DYMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score
Get the complete analysis for DYMDF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYMDF has been successfully added to your 
